Bayer initiated legal proceedings against Johnson & Johnson on Monday, accusing the rival pharmaceutical company of engaging in deceptive marketing practices for a prostate cancer treatment.

According to a complaint filed in Manhattan federal court, Johnson & Johnson launched a misleading promotional campaign targeting Bayer's drug Nubeqa in order to promote and exaggerate the purported advantages of its own medication, Erleada.

Bayer is seeking triple damages, the recovery of profits allegedly gained by Johnson & Johnson through improper means, and an injunction to halt what it describes as the rival's false advertising.

Johnson & Johnson has not yet issued an immediate response to requests for comment.